Compare ARVN & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | HDL |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 601.9M |
| IPO Year | 2018 | 2023 |
| Metric | ARVN | HDL |
|---|---|---|
| Price | $7.26 | $10.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 16 | 3 |
| Target Price | $13.93 | ★ $17.93 |
| AVG Volume (30 Days) | ★ 646.8K | 1.6K |
| Earning Date | 11-04-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $262,600,000.00 | N/A |
| Revenue This Year | $12.76 | $9.19 |
| Revenue Next Year | N/A | $14.22 |
| P/E Ratio | ★ $4.54 | $55.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.74 | $9.74 |
| 52 Week High | $14.22 | $18.33 |
| Indicator | ARVN | HDL |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 37.49 |
| Support Level | $6.74 | N/A |
| Resistance Level | $7.74 | $11.90 |
| Average True Range (ATR) | 0.36 | 0.24 |
| MACD | 0.08 | -0.10 |
| Stochastic Oscillator | 51.43 | 28.66 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.